theCOVIDboard

Full Version: EUA for mRNA treatment (bamlanivimab & etesevimab)
You're currently viewing a stripped down version of our content. View the full version with proper formatting.
FDA:
Quote:[On Feb 9], the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) who test positive for SARS-CoV-2 and who are at high risk for progressing to severe COVID-19. The authorized use includes treatment for those who are 65 years of age or older or who have certain chronic medical conditions.


In their ongoing effort to produce unpronounceable medications, the drug companies have outdone themselves. [Image: smile.png]